Type your tag names separated by a space and hit enter

Raynaud Phenomenon

Raynaud Phenomenon is a topic covered in the 5-Minute Clinical Consult.

To view the entire topic, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:

Medicine Central

-- The first section of this topic is shown below --



  • Idiopathic intermittent episodes of vasoconstriction of digital arteries, precapillary arterioles, and cutaneous arteriovenous shunts in response to cold, emotional stress, or blunt trauma
    • A triphasic color change of the fingers (occasionally the toes, rarely nipples) is the principal physical manifestation.
      • The initial color is white from extreme pallor, then blue from cyanosis, and finally with warming/vasodilatation, the skin appears red.
      • Thumbs are rarely involved.
    • Swelling, throbbing, and paresthesias are associated symptoms.
    • Primary
      • 80% of patients have primary disease.
      • Episodes are bilateral and nonprogressive.
      • Diagnosis confirmed if after 2 years of symptoms, no underlying connective tissue disease develops.
    • Secondary
      • Progressive and asymmetric
      • Vascular spasm is more frequent and more severe over time. Ulceration is rare; gangrene does not develop; 13% progress to digital fat pad atrophy and ischemic fingertip changes.
      • Typically associated with an underlying connective tissue disorder
  • System(s) affected: hematologic, lymphatic, immunologic, musculoskeletal, dermatologic, exocrine
Pregnancy Considerations
  • Raynaud phenomenon can appear as breast pain in lactating women (1).
  • Positive breast milk bacterial culture distinguishes mastitis from Raynaud phenomenon.

Geriatric Considerations
Initial appearance of Raynaud phenomenon after age 40 years often indicates underlying connective tissue disease.

Pediatric Considerations
Associated with systemic lupus erythematosus (SLE) and scleroderma


  • Primary
    • Predominant age: 14 years; ~1/4 begin >40 years
    • Predominant sex: female > male (4:1)
  • Secondary
    • Predominant age: >40 years
    • Predominant sex: no gender predilection

  • Primary: 3–12.5% of men; 6–20% of women (based on clinical history)
  • Secondary: ~1% of population

Etiology and Pathophysiology

Unknown. Dysregulation of vascular control mechanisms leads to imbalance between vasodilation and vasoconstriction. There is a reduced endothelin-dependent vasodilation activity and an increased vasoconstriction in peripheral vessels by overproduction of endothelin-1. 5-HT2 serotonin receptors may be involved in secondary Raynaud phenomenon. Platelet and blood viscosity abnormalities in secondary disease contribute to ischemic pathology.

Some studies suggest dominant inheritance pattern. ~1/4 of primary patients have a first-degree relative with Raynaud phenomenon.

Risk Factors

  • Existing autoimmune or connective tissue disorder
  • End-stage renal disease with hemodialysis may increase risk if a steal phenomenon associated with the arterial-venous shunt develops.
  • Primary and secondary disease associated with elevated homocysteine levels
  • Smoking is not associated with increased risk of Raynaud phenomenon but may worsen symptoms.

General Prevention

  • Avoid cold exposure.
  • Tobacco cessation
  • No relationship has been established between Raynaud phenomenon and vibratory tool use.

Commonly Associated Conditions

Secondary Raynaud

  • Scleroderma; SLE; polymyositis
  • Sjögren syndrome; occlusive vascular disease
  • Cryoglobulinemia

-- To view the remaining sections of this topic, please or purchase a subscription --


Stephens, Mark B., et al., editors. "Raynaud Phenomenon." 5-Minute Clinical Consult, 27th ed., Wolters Kluwer, 2019. Medicine Central, im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116512/all/Raynaud_Phenomenon.
Raynaud Phenomenon. In: Stephens MB, Golding J, Baldor RA, et al, eds. 5-Minute Clinical Consult. 27th ed. Wolters Kluwer; 2019. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116512/all/Raynaud_Phenomenon. Accessed March 24, 2019.
Raynaud Phenomenon. (2019). In Stephens, M. B., Golding, J., Baldor, R. A., & Domino, F. J. (Eds.), 5-Minute Clinical Consult. Available from https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116512/all/Raynaud_Phenomenon
Raynaud Phenomenon [Internet]. In: Stephens MB, Golding J, Baldor RA, Domino FJ, editors. 5-Minute Clinical Consult. Wolters Kluwer; 2019. [cited 2019 March 24]. Available from: https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116512/all/Raynaud_Phenomenon.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Raynaud Phenomenon ID - 116512 ED - Stephens,Mark B, ED - Golding,Jeremy, ED - Baldor,Robert A, ED - Domino,Frank J, BT - 5-Minute Clinical Consult, Updating UR - https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116512/all/Raynaud_Phenomenon PB - Wolters Kluwer ET - 27 DB - Medicine Central DP - Unbound Medicine ER -